

## Supplementary Materials for

### Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines


Marit J. van Gils<sup>1\*</sup>, A. H. Ayesha Lavell<sup>2#</sup>, Karlijn van der Straten<sup>1,3#</sup>, Brent Appelman<sup>4#</sup>, Ilja Bontjer<sup>1</sup>, Meliawati Poniman<sup>1</sup>, Judith A. Burger<sup>1</sup>, Melissa Oomen<sup>1</sup>, Joey H. Bouhuijs<sup>1</sup>, Marleen A. Slim<sup>5</sup>, Michiel Schinkel<sup>4</sup>, Lonneke A. van Vught<sup>3,6</sup>, Elke Wynberg<sup>1,5</sup>, Hugo D.G. van Willigen<sup>1</sup>, Marloes Grobбен<sup>1</sup>, Khadija Tejjani<sup>1</sup>, Jacqueline van Rijswijk<sup>1</sup>, Jonne Snitselaar<sup>1</sup>, Tom G. Caniels<sup>1</sup>, Amsterdam UMC COVID-19 S3/HCW study group, Alexander P. J. Vlaar<sup>6</sup>, Maria Prins<sup>3,5</sup>, Menno D. de Jong<sup>1</sup>, Godelieve J. de Bree<sup>4</sup>, Jonne J. Sikkens<sup>2,4\*</sup>, Marije K. Bomers<sup>2\*</sup>, Rogier W. Sanders<sup>1,7\*</sup>

Correspondence to: [r.w.sanders@amsterdamumc.nl](mailto:r.w.sanders@amsterdamumc.nl), [m.bomers@amsterdamumc.nl](mailto:m.bomers@amsterdamumc.nl),  
[j.sikkens@amsterdamumc.nl](mailto:j.sikkens@amsterdamumc.nl), [m.j.vangils@amsterdamumc.nl](mailto:m.j.vangils@amsterdamumc.nl)


#### **This PDF file includes:**

Figure S1 to S3


Table S1 to S5



**Figure S1: Binding and neutralization titer decline.** Binding titers to wild-type S protein (BAU/ml) of 1:100,000 diluted sera (A) and neutralization titers (IU/ml) of D614G pseudovirus (B) collected post complete vaccination and pre-booster for the four vaccination groups. The lower cutoff for binding was set at 30 BAU/ml (grey shading) for binding titers and at 2 IU/ml for neutralization titers. Lines connect the GMT of four weeks post complete vaccination and GMT of pre-booster titers per group. Vaccine groups are indicated by colors with BNT162b2 in green, mRNA-1273 in purple and AZD1222 in orange.



**Figure S2: Binding and neutralization titers post-vaccination against the VOCs.** (A) Paired binding titers to wild-type and VOCs S protein (BAU/ml) of 1:100,000 diluted sera collected post complete vaccination for the four vaccination groups (upper plot). The lower cut-off for binding was set at a 30 BAU/ml (grey shading). Mean  $\pm$  SEM fold reductions in binding titers against the VOCs in comparison to wild-type (lower plot). (B) Mean  $\pm$  SEM fold reductions in neutralization IC<sub>50</sub> titers against the VOCs pseudoviruses in comparison to neutralization IC<sub>50</sub> titers against D614G pseudovirus.



**Figure S3: Binding and neutralization post-vaccination titers against VOCs correlated.** Correlation between wild-type (A) and Beta (B) binding (BAU/ml) and neutralization titers (IU/ml). Spearman's rank correlation coefficients with p-values are indicated. (C) GMT (BAU/ml) of wild-type and VOCs plotted against the average reported vaccine efficacy against symptomatic infection (Table S4). Vaccine groups are indicated by colors with BNT162b2 in green, mRNA-1273 in purple, AZD1222 in orange and Ad26.COV2.S in blue. Circles represent WT data, squares for Alpha, diamond for Beta, nabla triangle for Gamma and delta triangle for Delta. Spearman's rank correlation coefficients with p-values are indicated. (D) Mean  $\pm$  SEM fold reductions in neutralization  $IC_{50}$  titers for the serum pools combined against the VOCs and VOIs pseudoviruses in comparison to  $IC_{50}$  titers against D614G pseudovirus.

**Table S1: Protein and pseudovirus S constructs contain the following mutations compared to the WT (Wuhan Hu-1; GenBank: MN908947.3).**

VOC S proteins						
Alpha B.1.1.7	Beta B.1.351	Gamma P.1	Beta B.1.351	Omicron B.1.1.529		
Δ69-70	L18F	L18F	T19R	A67V	S375F	Y505H
Δ144	D80A	T20N	G142D	Δ69-70	K417N	T547K
N501Y	D215G	P26S	E156G	T95I	N440K	D614G
A570D	Δ242-244	D138Y	Δ157-158	G142D	G446S	H655Y
D614G	K417N	R190S	L452R	Δ143-145	S477N	N679K
P681H	E484K	K417T	T478K	Δ211	T478K	P681H
T716I	N501Y	E484K	D614G	L212I	E484A	N764K
S982A	D614G	N501Y	P681R	ins214EPE	Q493K	D796Y
D1118H	A701V	D614G	D950N	G339D	G496S	N856K
		H655Y		S371L	Q498R	Q954H
		T1027I		S373P	N501Y	

VOC pseudovirus								
D614G B.1	Alpha B.1.1.7	Alpha +E484K B.1.1.7	Beta B.1.351	Beta +242-244 B.1.351	Gamma P.1	Delta B.1.617.2	Omicron B.1.1.529 BA.1	
D614G	Δ69-70	Δ69-70	L18F	L18F	L18F	T19R	A67V	Q498R
	Δ144	Δ144	D80A	D80A	T20N	G142D	Δ69-70	N501Y
	N501Y	E484K	D215G	D215G	P26S	E156G	T95I	Y505H
	A570D	N501Y	Δ242-244	L242H	D138Y	Δ157-158	G142D	T547K
	D614G	A570D	K417N	R246I	R190S	L452R	Δ143-145	D614G
	P681H	D614G	E484K	K417N	K417T	T478K	Δ211	H655Y
	T716I	P681H	N501Y	E484K	E484K	D614G	L212I	N679K
	S982A	T716I	D614G	N501Y	N501Y	P681R	ins214EPE	P681H
	D1118H	S982A	A701V	D614G	D614G	D950N	G339D	N764K
		D1118H		A701V	H655Y		S371L	D796Y
					T1027I		S373P	N856K
							S375F	Q954H
							K417N	N969K
							N440K	L981F
							G446S	
							S477N	
							T478K	
							E484A	
							Q493K	
							G496S	

VOI pseudovirus					
Epsilon B.1.429	Zeta P.2	Iota B.1.526	Kappa B.1.617.1	Lambda C.37	Mu B.1.621
S13I	E484K	L5F	T95I	G75V	Δ69-70
W152C	D614G	T95I	G142D	T76I	T95I
L452R	V1176F	D253G	E154K	Δ246-252	Y144S
D614G		E484K	L452R	D253N	Y145N
		D614G	E484Q	L452Q	R346K
		A701V	D614G	F490S	E484K
			P681R	D614G	N501Y
			Q1071H	T859N	A570D
					D614G
					P681H
					T716I
					D950N
					S982A

**Table S2: Reported vaccine efficacy (References; [2,3,5,14–18,20,22-24,36–52]).**

Vaccine	VOC	VE	Reference
BNT162b	WT	96%	Thomas et al
BNT162b	WT	95%	Polack et al
BNT162b	WT	91%	Chung et al
BNT162b	WT	92%	Nasreen et al
BNT162b	Alpha	68%	Meyer et al
BNT162b	Alpha	89%	Pilishvili et al
BNT162b	Alpha	98%	Glatman-Freedman et al
BNT162b	Alpha	95%	Andrews et al 2022-2
BNT162b	Alpha	97%	Katz et al
BNT162b	Alpha	87%	Kissling et al
BNT162b	Alpha	94%	Lopez Bernal et al
BNT162b	Alpha	82%	Martínez-Baz et al
BNT162b	Alpha	90%	Public Health England
BNT162b	Alpha	97%	Angel et al
BNT162b	Alpha	90%	Abbu-Raddad et al
BNT162b	Alpha	88%	Nasreen et al
BNT162b	Alpha	92%	Sheikh et al
BNT162b	Alpha	73%	Sheikh et al
BNT162b	Beta	75%	Abbu-Raddad et al
BNT162b	Beta	86%	Nasreen et al
BNT162b	Gamma	90%	Nasreen et al
BNT162b	Delta	90%	Prunas et al
BNT162b	Delta	87%	Kissling et al <a href="https://osf.io/3nhps/">https://osf.io/3nhps/</a>
BNT162b	Delta	93%	Powell et al
BNT162b	Delta	91%	Andrews et al 2022-1
BNT162b	Delta	93%	Reis et al
BNT162b	Delta	92%	Nordstrom et al
BNT162b	Delta	83%	Andrews et al 2022
BNT162b	Delta	44%	Tang et al
BNT162b	Delta	88%	Lopez Bernal et al
BNT162b	Delta	92%	Nasreen et al
BNT162b	Omicron	62%	Chemaitelly et al
BNT162b	Omicron	71%	Powell et al
BNT162b	Omicron	66%	Andrews et al 2022-2
mRNA-1273	WT	94%	Baden et al
mRNA-1273	WT	94%	Chung et al
mRNA-1273	WT	98%	Nasreen et al
mRNA-1273	Alpha	96%	Pilishvili et al
mRNA-1273	Alpha	92%	Nasreen et al
mRNA-1273	Delta	98%	Kissling et al <a href="https://osf.io/3nhps/">https://osf.io/3nhps/</a>
mRNA-1273	Delta	95%	Andrews et al 2022-1
mRNA-1273	Delta	96%	Nordstrom et al
mRNA-1273	Delta	95%	Andrews et al 2022-2
mRNA-1273	Delta	74%	Tang et al
mRNA-1273	Delta	94%	Nasreen et al
mRNA-1273	Omicron	45%	Chemaitelly et al
mRNA-1273	Omicron	76%	Andrews et al 2022-2
AZD1222	WT	62%	Voysey et al
AZD1222	Alpha	82%	Andrews et al 2022-2
AZD1222	Alpha	78%	Hitchings et al
AZD1222	Alpha	75%	Lopez Bernal et al
AZD1222	Alpha	89%	Public Health England
AZD1222	Alpha	87%	Nasreen et al

AZD1222	Delta	72%	Kissling et al <a href="https://osf.io/3nhps/">https://osf.io/3nhps/</a>
AZD1222	Delta	83%	Andrews et al 2022-1
AZD1222	Delta	68%	Nordstrom et al
AZD1222	Delta	64%	Andrews et al 2022-2
AZD1222	Delta	67%	Lopez Bernal et al
AZD1222	Delta	88%	Nasreen et al
AZD1222	Delta	79%	Sheikh et al
AZD1222	Delta	60%	Sheikh et al
AZD1222	Omicron	50%	Andrews et al 2022-2
Ad26.COVS.S	WT	67%	Sadoff et al
Ad26.COVS.S	Alpha	77%	Martínez-Baz et al
Ad26.COVS.S	Beta	64%	Sadoff et al
Ad26.COVS.S	Gamma	51%	Ranzani et al
Ad26.COVS.S	Delta	50%	Kissling et al <a href="https://osf.io/3nhps/">https://osf.io/3nhps/</a>
Ad26.COVS.S	Delta	42%	Martínez-Baz et al

**Table S3: Number of participants included in the binding or neutralization assay per time point per vaccine group.**

		<b>Binding</b>	<b>Neutralization</b>
BNT162b2	pre-vac	50	0
	post-V1	46	45
	post-V2	50	50
	+9m V2	42	36
	post-V3	37	34
mRNA-1273	pre-vac	25	0
	post-V1	40	30
	post-V2	39	29
	+6m V2	31	24
	post-V3	28	20
AZD1222	pre-vac	19	0
	post-V1	42	34
	post-V2	34	30
	+6m V2	32	29
	post-V3	26	23
Ad26.COVS.S	pre-vac	7	0
	post-V1	13	13
	+2m V1	13	13
	+7m V1	19	17
	post-V2*	18	16



**Table S4: Uni- and multivariable linear regression analysis.**

**Geometric means of binding levels against S wild type, BAU/ml (95% CI)**

	Post 1 vaccination		Post complete initial vaccination±		Pre-booster		Post-booster	
	Univariable	Multivariable¥	Univariable	Multivariable¥	Univariable	Multivariable¶	Univariable	Multivariable¥
BNT162b2	417 (324-536)	394 (280-554)	2967 (2419-3638)	2603 (1958-3460)	192 (138-268)	340 (120-964)	2840 (2321-3475)	2756 (2071-3668)
mRNA-1273	875 (666-1150)°°°	781 (512-1191)°°°	3461 (2739-4374)	2857 (1973-4137)	595 (404-876)°°°	386 (211-705)	3138 (2488-3958)	2993 (2097-4271)
AZD1222	79 (61-103)***	95 (60-150)***	219 (171-281)***	202 (136-301)***	37 (25-54)***	27 (13-55)***	1487 (1117-1892)***	1480 (997-2196)°°
Ad26.COV2.S	169 (105-271)**	169 (96-296)°°	169 (113-252)***	146 (91-234)***	107 (65-175)**	90 (49-165)*	1541 (1153-2058)***	1484 (1029-2140)***

\* significantly different from AZD1222 and BNT162b2 (p<0.05) and from mRNA-1273 (p<0.001)  
\*\* significantly different from AZD1222 (p=0.001) and mRNA-1273 (p<0.001)  
\*\*\* significantly different from both mRNA vaccines (p<0.001)  
°° significantly different from both mRNA vaccines (p<0.01)  
°°° significantly different from both vector vaccines and BNT162b2 (p<0.001)  
\*\* significantly different from AZD and BNT162b2 (p<0.01) and mRNA-1273 (p<0.001)  
°° significantly different from BNT162b2 (p<0.01) and mRNA-1273 (p<0.001)

± complete vaccination is 2 doses of BNT162b2, mRNA-1273 or AZD1222 of 1 dose of Ad26.COV2.S, for Ad26.COV2.S the same time point as post 1 vaccination  
¥ corrected for age and sex, geometric means and %95 CI represent median age of the cohort (47 years ) and female gender  
¶ corrected for age, sex and time between full vaccination and pre-booster serum sampling, geometric means and %95 CI represent median age of the cohort (47 years ), female gender and median time between full vaccination and pre-booster serum sampling (28 weeks)

**Geometric means of neutralizing antibodies against D614G, IC<sub>50</sub> in IU/ml (95% CI)**

	Post 1 vaccination		Post complete initial vaccination±		Pre-booster		Post-booster	
	Univariable	Multivariable‡	Univariable	Multivariable‡	Univariable	Multivariable¶	Univariable	Multivariable‡
BNT162b2	16 (12-20)	15 (10-20)	197 (160-243)	152 (113-204)	24 (18-33)	42 (15-113)	1154 (881-1511)	1192 (817-1738)
mRNA-1273	32 (24-42)**	28 (18-43)°	313 (239-409)**	220 (149-325)°	117 (79-172)°°°	92 (53-160)	1106 (778-1572)	1160 (717-1878)
AZD1222	13 (10-18)***	13 (8-22)**	26 (20-34)***	19 (12-29)***	8 (6-12)***	10 (5-19)▪	445 (321-617)***	379 (221-650)***
Ad26.COV2.S	14 (9-22)**	13 (8-23)**	14 (9-21)*	10 (6-16)*	21 (13-33)°°	20 (11-35)***	700 (473-1037)°	735 (445-1213)°

\* significantly different from AZD1222 (p<0.05) and both mRNA vaccines (p<0.001)

\*\* significantly different from BNT162b2 (p<0.01)

\*\*\* significantly different from both mRNA vaccines (p<0.001)

° significantly different from BNT162b2 (p<0.05)

°° significantly different from AZD1222 (p<0.01) and mRNA-1273 (p<0.001)

°°° significantly different from BNT162b2 (p<0.001)

▪ significantly different from BNT162b2 (p<0.05) and mRNA-1273 (p<0.001)

▪▪ significantly different from mRNA-1273 (p<0.01)

▪▪▪ significantly different from mRNA-1273 (p<0.001)

° significantly different from AZD1222 and BNT162b2 (p<0.05)

± complete vaccination is 2 doses of BNT162b2, mRNA-1273 or AZD1222 of 1 dose of Ad26.COV2.S

‡ corrected for age and sex, geometric means and %95 CI represent median age of the cohort (47 years ) and female gender

¶ corrected for age, sex and time between full vaccination and pre-booster serum sampling, geometric means and %95 CI represent median age of the cohort (47 years ), female gender and median time between full vaccination and pre-booster serum sampling (28 weeks)

**Comparison post initial vaccination series with convalescent cohort (COSCA)**

Post complete initial vaccination±, univariable	Geometric means of binding levels against S wild type, BAU/ml (95% CI)	Geometric means of neutralizing antibodies against D614G, IC <sub>50</sub> in IU/ml (95% CI)
BNT162b2	2967 (2212-3979)	197 (149-260)
mRNA-1273	3461 (2472-4847)	313 (218-448)*
AZD1222	219 (153-313)***	26 (18-37)***
Ad26.COV2.S	169 (95-300)***	14 (8-25)***
Convalescent	3463 (2630-4559)	175 (138-223)°°°

\*\*\* significantly different from both mRNA vaccines and convalescent (p<0.001)

\* significantly different from BNT162b2 (p=0.047)

°°° significantly different from both vector vaccines (p<0.001) and mRNA-1273 (0.009)

± complete vaccination is 2 doses of BNT162b2, mRNA-1273 or AZD1222 of 1 dose of Ad26.COV2.S

**Table S5: Individual binding and neutralization titers per vaccine group.**

Can be found in a separate extended data file